[Therapy of psoriasis vulgaris with efalizumab].
Mrowietz
Ulrich
U
Universitäts-Hauklinik Kiel. UMrowietz@dermatology.uni-kiel.de
Barth
Joachim
J
Boehncke
Wolf-Henning
WH
Reich
Kristian
K
Rosenbach
Thomas
T
Streit
Volker
V
Wozel
Gottfried
G
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D008134:Long-Term Care; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab